treatment
Isolated local-regional recurrence should be treated like a new primary with a curative intent including adjuvant treatment modalities as appropriate [II, B] . Treatment for systemic disease is palliative. Goals of treatment include improving and maintaining quality of life and prolongation of survival [I, A] . Treatment of metastatic breast cancer usually involves hormone therapy or chemotherapy with or without trastuzumab. Radiation therapy is an integral part of palliative treatment. For limited metastatic presentations surgery may be considered. Bisphosphonates are effective in hypercalcemia and palliate symptoms and decrease risk for pathological fractures from clinically evident bone metastases [I, A]. The timing and optimal duration of administration of bisphosphonates are unknown.
patients with hormone receptor-positive tumor
Patients should start with endocrine therapy (Table 2) except if a clinically aggressive disease mandates a quicker response.
premenopausal patients
If no prior adjuvant tamoxifen or if discontinued for >12 months: tamoxifen with ovarian ablation (luteinizing 
patients with hormone receptor-negative tumor
Patients having hormone receptor-negative tumors and/or having progressed on hormone therapy are candidates for cytotoxic chemotherapy (Table 3 ). The selection of the regimen should be on the basis of the tumor and patient characteristics (e.g. symptoms, performance status, extent of metastatic disease, presence or absence of comorbid medical conditions, previous adjuvant systemic therapy) and patient/physician preferences. At this time, there are no data supporting the superiority of any particular regimen. The optimal treatment duration for patients with responsive or stable disease is unknown. Chemotherapy can be polychemotherapy or agents can be used in sequence. Prolonged treatment may result in improved quality of life and time to progression, but there is no evidence for survival advantage [I, A].
Selection of commonly used chemotherapy regimens is shown in Table 3 . Anthracyclines, taxanes, capecitabine, vinorelbine, fluorouracil as continuous infusion and gemcitabine are examples of commonly used single agents.
There is no standard approach for patients requiring second-or further-line treatment. Continuing beyond third-line chemotherapy may be justified in patients with good performance status and response to previous chemotherapy.
There is no evidence of an advantage in terms of overall or relapse-free survival for patients receiving high-dose chemotherapy.
patients with overexpression of HER2/neu
Patients with metastatic breast cancer with overexpression of HER2/neu in IHC and/or in situ hybridization with FISH or CISH should be treated with trastuzumab with or without nonanthracycline-containing chemotherapy [II, B] . Cardiac monitoring should be performed before and while on trastuzumab therapy.
Discontinuation of trastuzumab after disease progression is standard care, although some benefit from the treatment beyond disease progression has been reported with changing chemotherapy regimen.
Lapatinib has shown a significant increase in time to progression in combination with capecitabine in patients progressing after trastuzumab.
response evaluation
Response evaluation is recommended after 3 months of endocrine therapy and after two or three cycles of chemotherapy by clinical evaluation, subjective symptom evaluation, blood tests and repeating the initially abnormal radiologic examinations. Serum tumor markers (CA 15-3) may be helpful in monitoring response of not easily measurable disease but should not be used as the only determinant for treatment decision.
follow-up
Follow-up after the treatment of local-regional recurrence may be carried out as for primary breast cancer. Patients must be 
